TSVT News and Press, 2seventy bio Inc. From 03/22/22

Closed $170M private placement with leading healthcare investors ABECMA generated $158M U.S. commercial revenue in 2021; tracking toward upper end of $250-300M U.S. revenue guidance for 2022 Internal cost reduction measures reduce net cash spend guidance to $190-220M f...

2seventy bio (NASDAQ:TSVT) agreed to sell ~13.9M shares to a select group of institutional and accredited investors in a private placement. On financing closure, the company will receive gross proceeds of ~$170M based on $12.2/share (Mar.15 closing price). The financing is expected ...

Proceeds to support 2seventy bio’s pipeline of novel cell therapy programs Financing, combined with reduced net cash spend and ABECMA commercial progress, supports extension of cash runway into 2025 2seventy bio, Inc . (Nasdaq: TSVT), a leading immuno-onco...

PTAB turned the CRISPR industry upside down, with sleepy biotechs becoming market favorites overnight and leading companies dropping by double-digit rates. NTLA management will likely talk down the effects of the patent ruling, but given the new dynamics, this speculative trade has be...

Steven Bernstein, M.D. appointed to chief medical officer Susan Abu-Absi, Ph.D. promoted to chief technology & manufacturing officer 2seventy bio, Inc . (NASDAQ: TSVT) announced that Steven Bernstein, M.D. will join the company effective today and assume the ...

2seventy bio, Inc . (Nasdaq: TSVT) announced today that it will present at the following upcoming investor conferences: SVB Leerink 10 th Annual Global Healthcare Conference; Fireside chat, Wednesday, February 16, 2022, at 2:20pm ET Cowen Virtual 42 nd Annual...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. “I a...

ABECMA generated approximately $150M U.S. revenue in 2021, equally shared by 2seventy bio and Bristol Myers Squibb; anticipate continued ABECMA growth in 2022 with $250-300M U.S. revenue bbT369 IND cleared - program tests three layers of innovation in B-NHL; achieved goal of t...

Collaboration further validates 2seventy bio’s megaTAL ™ gene editing platform with potential applicability across company’s oncology pipeline 2seventy bio is eligible to receive $40M in near-term payments, in addition to future milestone payments and ...

The healthcare sector has gained significant importance since the onset of the pandemic. Moreover, the industry is evolving with unique product launches and technological advancements. The healthcare sector has seen several IPOs this year. Healthcare companies 2seventy (TSVT), Regencell (RGC)...